Researchers sought to evaluate preferences related to treatment features of BCMA-directed bispecific antibodies and CAR-T therapy.

Our real-world findings indicate that most patients undergoing multiple lines of therapy experience persistent treatment refractoriness and low response rates,” the researchers wrote.

Melphalan flufenamide (melflufen) is approved in Europe for relapsed/refractory multiple myeloma, but the FDA withdrew its ...

GSK plc has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Blenrep. In the UK, ...

A real-world study has reinforced the efficacy and safety of teclistamab in heavily pretreated patients with ...

Early infection incidence in patients with multiple myeloma following treatment with cilta-cel infusion highlights the ...

GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities ...

Cartesian Therapeutics, Inc.’s RNAC share price has dipped by 6.62%, which has investors questioning if this is right time to ...

Legend Biotech (LEGN) shares jumped 5% over the past week on heavy trading volume as investors responded to impressive ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...